McGovern Kerri, Ghaly Maged, Esposito Michael, Barnaby Keara, Seetharamu Nagashree
Division of Hematology & Medical Oncology, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, 11042 USA.
Department of Radiation Oncology, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, 11042 USA.
Future Sci OA. 2019 Apr 10;5(5):FSO378. doi: 10.2144/fsoa-2018-0123. eCollection 2019 Jun.
Radiation recall pneumonitis (RRP) is an entity described as pneumonitis localized to a previously irradiated field after exposure to a systemic agent. It has previously been described in the literature in the context of chemotherapeutic agents as well as certain biologics. With immunotherapy taking a more prominent role in the treatment of several different malignancies and its own baseline risk of pneumonitis, it is important to explore the likelihood of RRP, specifically in those patients who have been previously treated with radiation therapy. The current literature regarding RRP with checkpoint inhibitors is reviewed in this article. Alongside this review, we report a case of RRP after pembrolizumab initiation in a patient in our practice.
放射性肺炎(RRP)是一种被描述为在接触全身用药后局限于先前照射部位的肺炎。此前在文献中已有关于化疗药物以及某些生物制剂引发RRP的描述。随着免疫疗法在多种不同恶性肿瘤治疗中发挥着越来越重要的作用,且其本身存在肺炎的基线风险,因此探讨RRP发生的可能性很重要,尤其是在那些先前接受过放射治疗的患者中。本文对目前关于检查点抑制剂引发RRP的文献进行了综述。在本次综述的同时,我们报告了我们诊所中一名患者在开始使用帕博利珠单抗后发生RRP的病例。